farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2022.149farmaec-707Research ArticleORIGINAL ARTICLESОРИГИНАЛЬНЫЕ ПУБЛИКАЦИИDrug therapy for obesity in the Russian Federation: pharmacoepidemiological studyЛекарственная терапия ожирения в Российской Федерации: фармакоэпидемиологическое исследованиеhttps://orcid.org/0000-0002-1838-9961СтрижелецкийВ. В.StrizheletskyV. V.

Стрижелецкий Валерий Викторович – доктор медицинских наук, профессор кафедры факультетской хирургии медицинского факультета Санкт-Петербургский ГУ, главный врач СПб ГБУЗ «Городская больница Святого Великомученика Георгия; WoS ResearcherID: G-6004-2015; РИНЦ SPIN-код: 9802-2920.

Университетская наб., д. 7–9, Санкт-Петербург 199034; Северный пр-т, д. 1, Санкт-Петербург 194354

Valery V. Strizheletsky – Dr. Med. Sc., Professor, Chair of Faculty Surgery, Faculty of Medicine, Saint Petersburg SU; Chief Physician, Saint George City Hospital. WoS ResearcherID: G-6004-2015; RSCI SPIN-code: 9802-2920.

7–9 Universitetskaya Emb., Saint Petersburg 199034; 1 Severnyy Ave., Saint Petersburg 194354

https://orcid.org/0000-0001-7704-9900ГомонЮ. М.GomonYu. М.

фармакологии и доказательной медицины Первый Санкт-Петербургский ГМУ им. академика И.П. Павлова» Минздрава России, врач – клинический фармаколог СПб ГБУЗ ГБ Святого Великомученика Георгия; WoS ResearcherID: O-9443-2018; Scopus Author ID: 57217520417; РИНЦ SPIN-код: 1839-9558.

Северный пр-т, д. 1, Санкт-Петербург 194354; ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022

Yulia M. Gomon – Dr. Med. Sc., Professor, Chair of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov SMU; Clinical Pharmacologist, Saint George City Hospital; WoS ResearcherID: O-9443-2018; Scopus Author ID: 57217520417; RSCI SPIN-code: 1839-9558.

1 Severnyy Ave., Saint Petersburg 194354; 6-8 Lev Tolstoy Str., Saint Petersburg 197022

gomonmd@yandex.ruhttps://orcid.org/0000-0003-0587-6258СпичаковаЕ. А.SpichakovaЕ. А.

Спичакова Ева Александровна – врач-хирург Городского центра инновационных медицинских технологий.

Северный пр-т, д. 1, Санкт-Петербург 194354

Eva A. Spichakova – Surgeon.

1 Severnyy Ave., Saint Petersburg 194354

https://orcid.org/0000-0002-1919-2909КолбинА. С.KolbinА. S.

Колбин Алексей Сергеевич – доктор медицинских наук, профессор кафедры фармакологии медицинского факультета Санкт-Петербургский ГУ, заведующий кафедрой клинической фармакологии и доказательной медицины ФГБОУ ВО Первый Санкт-Петербургский ГМУ им. академика И.П. Павлова. WoS ResearcherID: G-5537-2015; Scopus Author ID: 19836020100; РИНЦ SPIN-код: 7966-0845.

Университетская наб., д. 7–9, Санкт-Петербург 199034; ул. Льва Толстого, д. 6-8, Санкт-Петербург 197022

Aleksey S. Kolbin – Dr. Med. Sc., Professor, Chair of Pharmacology, Faculty of Medicine, Saint Petersburg SU; Chief of Chair of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov SMU. WoS ResearcherID: G-5537-2015; Scopus Author ID: 19836020100; RSCI SPIN-code: 7966-0845.

7–9 Universitetskaya Emb., Saint Petersburg 1990346-8 Lev Tolstoy Str., Saint Petersburg 197022

https://orcid.org/0000-0003-4881-2991КаляпинА. А.KalyapinА. А.

Каляпин Антон Андреевич – заместитель директора по продажам и связям с поставщиками компании.

Ленинградский пр-т, д. 37А, корп. 14, Москва 125167

Anton A. Kalyapin – Deputy Director of Sales and Supplier Relations, IQVIA Russia and CIS.

37А corp. 14 Leningradskiy Ave., Moscow 125167

https://orcid.org/0000-0002-8423-8002МакаровС. А.MakarovS. А.

Макаров Сергей Анатольевич – кандидат медицинских наук, руководитель Городского центра инновационных медицинских технологий.

Северный пр-т, д. 1, Санкт-Петербург 194354

Sergey A. Makarov – MD, PhD, Head of City Center for Innovative Medical Technologies.

1 Severnyy Ave., Saint Petersburg 194354

ЛомияА. Б.LomiyaА. B.

Ломия Александр Бадриевич – врач-хирург Городского центра инновационных медицинских технологий.

Северный пр-т, д. 1, Санкт-Петербург 194354

Aleksandr B. Lomiya – Surgeon, City Center for Innovative Medical Technologies.

1 Severnyy Ave., Saint Petersburg 194354

СултановаФ. М.SultanovaF. М.

Султанова Флора Миргалимовна – врач-хирург, координатор учебного центра Российского общества эндоскопических хирургов.

Северный пр-т, д. 1, Санкт-Петербург 194354

Flora M. Sultanova – Surgeon, Coordinator of the Russian Society of Endoscopic Surgeons Training Center.

1 Severnyy Ave., Saint Petersburg 194354

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»; Санкт-Петербургское государственное бюджетное учреждение здравоохранения «Городская больница Святого Великомученика Георгия»РоссияSaint Petersburg State University; Saint George City HospitalRussian FederationСанкт-Петербургское государственное бюджетное учреждение здравоохранения «Городская больница Святого Великомученика Георгия»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияSaint George City Hospital; First Pavlov State Medical UniversityRussian FederationСанкт-Петербургское государственное бюджетное учреждение здравоохранения «Городская больница Святого Великомученика Георгия»РоссияSaint George City HospitalRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияSaint Petersburg State University; First Pavlov State Medical UniversityRussian FederationIQVIA Россия и СНГРоссияIQVIA Russia and CISRussian Federation202209102022153320331Copyright © Strizheletsky V.V., Gomon Y.М., Spichakova Е.А., Kolbin А.S., Kalyapin А.А., Makarov S.А., Lomiya А.B., Sultanova F.М., 20222022Стрижелецкий В.В., Гомон Ю.М., Спичакова Е.А., Колбин А.С., Каляпин А.А., Макаров С.А., Ломия А.Б., Султанова Ф.М.Strizheletsky V.V., Gomon Y.М., Spichakova Е.А., Kolbin А.S., Kalyapin А.А., Makarov S.А., Lomiya А.B., Sultanova F.М.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/707Objective

Objective: аssessment of orlistat, liraglutide and sibutramine consumption in the Russian Federation as drugs recommended by the Russian clinical guidelines for the pharmacotherapy of obesity.

Material and methods

Material and methods. From IQVIA database, the information was selected on retail sales and procurement of the specified drugs at the expense of the federal and regional budgets in the period of 2011–2021. The consumed volumes of each drug were recalculated into the number of defined daily doses (DDDs) for each international nonproprietary name in accordance with the World Health Organization methodology.

Results

Results. It was demonstrated that over a 10-year period there was a tendency to reduce the consumption of drugs for the treatment of obesity from 83.03 million DDDs in 2011 to 71.7 million in 2021. Sibutramine consumption dominated throughout the observation period: its share ranged from 76% to 84%. The proportion of people receiving obesity pharmacotherapy in the Russian Federation was about 0.5%. Herewith 58–66% of DDDs sales took place in 3 regions: Moscow, Moscow Region and Saint Petersburg.

Conclusion

Conclusion. Low efficacy, high frequency of adverse effects, frequent weight gain after therapy termination, as well as low orientation of doctors to the need for pharmacotherapy are probably the main factors determining the low prevalence of using drugs for the treatment of obesity in Russia.

Цель

Цель: оценка объемов потребления препаратов орлистат, лираглутид и сибутрамин в Российской Федерации как средств, рекомендованных Российской ассоциацией эндокринологов и Российской ассоциацией бариатрических хирургов в качестве медикаментозной терапии ожирения.

Материал и методы

Материал и методы. Из базы данных IQVIA была отобрана информация об объемах продаж в розничной сети, закупок за счет средств федерального и региональных бюджетов указанных лекарственных средств в период 2011–2021 гг. Проведен перерасчет потребленных объемов каждого препарата в количество средних установленных суточных доз (англ. defined daily dose, DDD) по  каждому международному непатентованному наименованию в соответствии с методологией Всемирной организации здравоохранения.

Результаты

Результаты. Продемонстрировано, что за 10-летний период имеется тенденция к сокращению потребления лекарственных средств для лечения ожирения с 83,03 млн DDD в 2011 г. до 71,7 млн в 2021 г. В структуре потребления на всем протяжении наблюдения доминировал сибутрамин: его доля составляла от 76% до 84%. Доля лиц, получающих фармакотерапию ожирения в России, составляет около 0,5%. При этом 58–66% продаж DDD были осуществлены в трех регионах: г. Москва, Московская обл. и г. Санкт-Петербург.

Заключение

Заключение. Низкая эффективность, высокая частота нежелательных реакций, частый набор веса после отмены терапии, а также недостаточная ориентированность врачей на необходимость проведения фармакотерапии – вероятно, основные факторы, определяющие низкую распространенность применения медикаментозных методов лечения ожирения в России.

ожирениеморбидное ожирениефармакотерапиямедикаментозное лечениефармакоэпидемиологияobesitymorbid obesitypharmacotherapydrug treatmentpharmacoepidemiologyReferencesВсемирная организация здравоохранения. Ожирение и избыточный вес. URL: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight (дата обращения 16.04.2022).World Health Organization. Obesity and overweight. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 16.04.2022).Здравоохранение в России 2021. URL: https://rosstat.gov.ru/folder/210/document/13218 (дата обращения 16.04.2022).Health care in Russia 2021. Available at: https://rosstat.gov.ru/folder/210/document/13218 (in Russ.) (accessed 16.04.2022).Wilson P., D’Agostino R., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162 (16): 1867–72. https://doi.org/10.1001/archinte.162.16.1867.Wilson P., D’Agostino R., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162 (16): 1867–72. https://doi.org/10.1001/archinte.162.16.1867.Poirier P., Giles T., Bray G., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113 (6): 898– 918. https://doi.org/10.1161/CIRCULATIONAHA.106.171016.Poirier P., Giles T., Bray G., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113 (6): 898– 918. https://doi.org/10.1161/CIRCULATIONAHA.106.171016.Manninen P., Riihimäki H., Heliövaara M., Mäkelä P. Overweight, gender, and knee osteoarthritis. Int J Obes Relat Metab Disord. 1996; 20 (6): 595–7.Manninen P., Riihimäki H., Heliövaara M., Mäkelä P. Overweight, gender, and knee osteoarthritis. Int J Obes Relat Metab Disord. 1996; 20 (6): 595–7.Ferini-Strambi L., Fantini M.L., Castronovo C. Epidemiology of obstructive sleep apnea syndrome. Minerva Med. 2004; 95 (3): 187–202.Ferini-Strambi L., Fantini M.L., Castronovo C. Epidemiology of obstructive sleep apnea syndrome. Minerva Med. 2004; 95 (3): 187–202.Basen-Engquist K., Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. 2011; 13 (1): 71–6. https://doi.org/10.1007/s11912-010-0139-7.Basen-Engquist K., Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. 2011; 13 (1): 71–6. https://doi.org/10.1007/s11912-010-0139-7.Tremmel M., Gerdtham U.G., Nilsson P.M., Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017; 14 (4): 435. https://doi.org/10.3390/ijerph14040435.Tremmel M., Gerdtham U.G., Nilsson P.M., Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017; 14 (4): 435. https://doi.org/10.3390/ijerph14040435.Puhl R., Heuer C. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009; 17 (5): 941–64. https://doi.org/10.1038/oby.2008.636.Puhl R., Heuer C. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009; 17 (5): 941–64. https://doi.org/10.1038/oby.2008.636.Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation. 2012; 125 (17): 2156–64. https://doi.org/10.1161/CIRCULATIONAHA.111.028381.Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation. 2012; 125 (17): 2156–64. https://doi.org/10.1161/CIRCULATIONAHA.111.028381.Astrup A. Drug management of obesity – efficacy versus safety. N Engl J Med. 2010; 363 (3): 288–90. https://doi.org/10.1056/NEJMe1004076.Astrup A. Drug management of obesity – efficacy versus safety. N Engl J Med. 2010; 363 (3): 288–90. https://doi.org/10.1056/NEJMe1004076.Adan R.A. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013; 36 (2): 133–40. https://doi.org/10.1016/j.tins.2012.12.001.Adan R.A. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013; 36 (2): 133–40. https://doi.org/10.1016/j.tins.2012.12.001.Ожирение. Клинические рекомендации. 2020 г. URL: https://edu.endocrincentr.ru/sites/default/files/recommendation_pdf/kr28.pdf (дата обращения 16.04.2022).Obesity. Guidelines. 2020. Available at: https://edu.endocrincentr.ru/sites/default/files/recommendation_pdf/kr28.pdf (in Russ.) (accessed 16.04.2022).Распоряжение Правительства РФ от 23.12.2021 № 3781-р. URL: http://publication.pravo.gov.ru/Document/View/0001202112290013 (дата обращения 16.04.2022).Order of the Government of the RF of 23.12.2021 No. 3781-r. Available at: http://publication.pravo.gov.ru/Document/View/0001202112290013 (in Russ.) (accessed 16.04.2022).Khera R., Murad M.H., Chandar A.K., et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016; 315 (22): 2424–34. https://doi.org/10.1001/jama.2016.7602.Khera R., Murad M.H., Chandar A.K., et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016; 315 (22): 2424– 34. https://doi.org/10.1001/jama.2016.7602.Nelson D.L., Gehlert D.R. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2016; 29 (1): 49–60. https://doi.org/10.1385/endo:29:1:49.Nelson D.L., Gehlert D.R. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2016; 29 (1): 49–60. https://doi.org/10.1385/endo:29:1:49.McMahon F.G., Fujioka K., Singh B.N., et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000; 160 (14): 2185–91. https://doi.org/10.1001/archinte.160.14.2185.McMahon F.G., Fujioka K., Singh B.N., et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000; 160 (14): 2185–91. https://doi.org/10.1001/archinte.160.14.2185.Smith I.G., Goulder M.A. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001; 50 (6): 505–12.Smith I.G., Goulder M.A. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001; 50 (6): 505–12.Fujioka K., Seaton T.B., Rowe E., et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000; 2 (3): 175–87. https://doi.org/10.1046/j.1463-1326.2000.00081.x.Fujioka K., Seaton T.B., Rowe E., et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000; 2 (3): 175–87. https://doi.org/10.1046/j.1463-1326.2000.00081.x.Jame W., Caterson I., Coutinho W., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363 (10): 905–17. https://doi.org/10.1056/NEJMoa1003114.Jame W., Caterson I., Coutinho W., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363 (10): 905–17. https://doi.org/10.1056/NEJMoa1003114.Kang J.G., Park C.Y. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012; 36 (1): 13–25. https://doi.org/10.4093/dmj.2012.36.1.13.Kang J.G., Park C.Y. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012; 36 (1): 13–25. https://doi.org/10.4093/dmj.2012.36.1.13.Drent M.L., Larsson I., William-Olsson T., et al. Orlistat (Ro 180647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995; 19 (4): 221–6.Drent M.L., Larsson I., William-Olsson T., et al. Orlistat (Ro 180647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995; 19 (4): 221–6.Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281 (3): 235–42. https://doi.org/10.1001/jama.281.3.235.Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281 (3): 235–42. https://doi.org/10.1001/jama.281.3.235.Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. 1-year randomized double-blind study. Diabetes Care. 1998; 21 (8): 1288–94. https://doi.org/10.2337/diacare.21.8.1288.Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. 1-year randomized double-blind study. Diabetes Care. 1998; 21 (8): 1288–94. https://doi.org/10.2337/diacare.21.8.1288.Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4 (5): 639–44. https://doi.org/10.1016/j.cgh.2006.02.004.Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4 (5): 639–44. https://doi.org/10.1016/j.cgh.2006.02.004.McDuffie J.R., Calis K.A., Booth S.L., et al. Effects of orlistat on fat soluble vitamins in obese adolescents. Pharmacotherapy. 2002; 22 (7): 814–22. https://doi.org/10.1592/phco.22.11.814.33627.McDuffie J.R., Calis K.A., Booth S.L., et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002; 22 (7): 814–22. https://doi.org/10.1592/phco.22.11.814.33627.Drucker D.J. The biology of incretin hormones. Cell Metab. 2006; 3 (3): 153–65. https://doi.org/10.1016/j.cmet.2006.01.004.Drucker D.J. The biology of incretin hormones. Cell Metab. 2006; 3 (3): 153–65. https://doi.org/10.1016/j.cmet.2006.01.004.Sisley S., Gutierrez-Aguilar R., Scott M., et al. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest. 2014; 124 (6): 2456–63. https://doi.org/10.1172/JCI72434.Sisley S., Gutierrez-Aguilar R., Scott M., et al. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest. 2014; 124 (6): 2456–63. https://doi.org/10.1172/JCI72434.Prigeon R.L., Quddusi S., Paty B., D’Alessio D.A. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab. 2003; 285 (4): E701–7. https://doi.org/10.1152/ajpendo.00024.2003.Prigeon R.L., Quddusi S., Paty B., D’Alessio D.A. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab. 2003; 285 (4): E701–7. https://doi.org/10.1152/ajpendo.00024.2003.González N., Acitores A., Sancho V., et al. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept. 2005; 126 (3): 203–11. https://doi.org/10.1016/j.regpep.2004.10.002.González N., Acitores A., Sancho V., et al. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept. 2005; 126 (3): 203–11. https://doi.org/10.1016/j.regpep.2004.10.002.Willms B., Werner J., Holst J.J., et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81 (1): 327–32. https://doi.org/10.1210/jcem.81.1.8550773.Willms B., Werner J., Holst J.J., et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81 (1): 327–32. https://doi.org/10.1210/jcem.81.1.8550773.Timmers L., Henriques J.P., de Kleijn D.P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53 (6): 501– 10. https://doi.org/10.1016/j.jacc.2008.10.033.Timmers L., Henriques J.P., de Kleijn D.P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53 (6): 501–10. https://doi.org/10.1016/j.jacc.2008.10.033.Hui H., Farilla L., Merkel P., Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002; 146 (6): 863–9. https://doi.org/10.1530/eje.0.1460863.Hui H., Farilla L., Merkel P., Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002; 146 (6): 863–9. https://doi.org/10.1530/eje.0.1460863.Agersø H., Jensen L.B., Elbrønd B., et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new longacting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45 (2): 195–202. https://doi.org/10.1007/s00125-001-0719-z.Agersø H., Jensen L.B., Elbrønd B., et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45 (2): 195– 202. https://doi.org/10.1007/s00125-001-0719-z.Degn K.B., Juhl C.B., Sturis J., et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alphaand beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53 (5): 1187–94. https://doi.org/10.2337/diabetes.53.5.1187.Degn K.B., Juhl C.B., Sturis J., et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alphaand beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53 (5): 1187–94. https://doi.org/10.2337/diabetes.53.5.1187.Vilsbøll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30 (6): 1608–10. https://doi.org/10.2337/dc06-2593.Vilsbøll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30 (6): 1608–10. https://doi.org/10.2337/dc06-2593.Bettge K., Kahle M., Abd El Aziz M.S., et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017; 19 (3): 336–47. https://doi.org/10.1111/dom.12824.Bettge K., Kahle M., Abd El Aziz M.S., et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017; 19 (3): 336–47. https://doi.org/10.1111/dom.12824.Pi-Sunyer X., Astrup A., Fujioka K., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373 (1): 11–22. https://doi.org/10.1056/NEJMoa1411892.Pi-Sunyer X., Astrup A., Fujioka K., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373 (1): 11–22. https://doi.org/10.1056/NEJMoa1411892.IQVIA Россия и СНГ. URL: https://www.iqvia.com/ru-ru/locations/russia (дата обращения 16.04.2022).IQVIA Russia and CIS. Available at: https://www.iqvia.com/ru-ru/ locations/russia (in Russ.) (accessed 16.04.2022).WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index 2018. URL: https://www.whocc.no/atc_ddd_index/ (дата обращения 16.04.2022).WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index 2018. Available at: https://www.whocc.no/atc_ddd_index/ (accessed 16.04.2022).WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2022. URL: https://www.whocc.no/filearchive/publications/2022_guidelines_web.pdf (дата обращения 16.04.2022).WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2022. Available at: https://www.whocc.no/filearchive/publications/2022_guidelines_web.pdf (accessed 16.04.2022).Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19 (2): 104–12. https://doi.org/10.14341/DM2004116-17.Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016; 19 (2): 104–12 (in Russ.). https://doi.org/10.14341/DM2004116-17.Федеральная служба государственной статистики. Численность населения Российской Федерации по полу и возрасту на 1 января 2016 года. URL: https://gks.ru/bgd/regl/B16_111/Main.htm (дата обращения 16.04.2022).Federal State Statistics Service. Population of the Russian Federation by gender and age as of January 1, 2016. Available at: https://gks.ru/bgd/regl/B16_111/Main.htm (in Russ.) (accessed 16.04.2022).Xia Y., Kelton C.M., Guo J.J., et al. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring). 2015; 23 (8): 1721–8. https://doi.org/10.1002/oby.21136.Xia Y., Kelton C.M., Guo J.J., et al. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring). 2015; 23 (8): 1721–8. https://doi.org/10.1002/oby.21136.Thomas C.E., Mauer E.A., Shukla A.P., et al. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016; 24 (9): 1955–61. https://doi.org/10.1002/oby.21533.Thomas C.E., Mauer E.A., Shukla A.P., et al. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016; 24 (9): 1955–61. https://doi.org/10.1002/oby.21533.Colbert J.A., Jangi S. Training physicians to manage obesity – back to the drawing board. N Engl J Med. 2013; 369 (15): 1389–91. https://doi.org/10.1056/NEJMp1306460.Colbert J.A., Jangi S. Training physicians to manage obesity – back to the drawing board. N Engl J Med. 2013; 369 (15): 1389–91. https://doi.org/10.1056/NEJMp1306460.Jensen M.D., Ryan D.H., Apovian C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129 (25 Suppl. 2): S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.Jensen M.D., Ryan D.H., Apovian C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129 (25 Suppl. 2): S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.Sjöström L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351 (26): 2683–93. https://doi.org/10.1056/NEJMoa035622.Sjöström L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351 (26): 2683–93. https://doi.org/10.1056/NEJMoa035622.Pories W.J., Swanson M.S., MacDonald K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995; 222 (3): 339–52. https://doi.org/10.1097/00000658-199509000-00011.Pories W.J., Swanson M.S., MacDonald K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995; 222 (3): 339–52. https://doi.org/10.1097/00000658-199509000-00011.Carlsson L.M., Peltonen M., Ahlin S., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367 (8): 695–704. https://doi.org/10.1056/NEJMoa1112082.Carlsson L.M., Peltonen M., Ahlin S., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367 (8): 695–704. https://doi.org/10.1056/NEJMoa1112082.Российский национальный бариатрический реестр. URL: https://bareoreg.ru/ (дата обращения 16.04.2022).Russian National Bariatric Registry. Available at: https://bareoreg. ru/ (in Russ.) (accessed 16.04.2022).Robinson M.K. Surgical treatment of obesity – weighing the facts. N Engl J Med. 2009; 361 (5): 520–1. https://doi.org/10.1056/NEJMe0904837.Robinson M.K. Surgical treatment of obesity – weighing the facts. N Engl J Med. 2009; 361 (5): 520–1. https://doi.org/10.1056/NEJMe0904837.Marcotte E., Chand B. Management and prevention of surgical and nutritional complications after bariatric surgery. Surg Clin North Am. 2016; 96 (4): 843–56. https://doi.org/10.1016/j.suc.2016.03.006.Marcotte E., Chand B. Management and prevention of surgical and nutritional complications after bariatric surgery. Surg Clin North Am. 2016; 96 (4): 843–56. https://doi.org/10.1016/j.suc.2016.03.006.Shikora S.A., Kruger R.S. Jr., Blackburn G.L. Best practices in policy and access (coding and reimbursement) for weight loss surgery. Obesity (Silver Spring). 2009; 17 (5): 918–23. https://doi.org/10.1038/oby.2008.573.Shikora S.A., Kruger R.S. Jr., Blackburn G.L. Best practices in policy and access (coding and reimbursement) for weight loss surgery. Obesity (Silver Spring). 2009; 17 (5): 918–23. https://doi.org/10.1038/oby.2008.573.Постановление Правительства РФ от 28.12.2021 № 2505 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2022 год и на плановый период 2023 и 2024 годов». URL: https://base.garant.ru/403335795/ (дата обращения 16.04.2022).Decree of the Government of the RF of 28.12.2021 No. 2505 “On the Program of state guarantees of free medical care to citizens for 2022 and for the planning period of 2023 and 2024”. Available at: https://base.garant.ru/403335795/ (in Russ.) (accessed 16.04.2022).

The authors declare that there are no conflicts of interest present.